Skip to content
6-K

Foreign Interim / Material

Abivax S.A. AAVXF ABVX

0001956827-25-000021

← back to feed
Filed
Jun 2, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2025 · Mar 31, 2025 63.38M sh
Shares Diluted Q1 2025 · Mar 31, 2024 62.92M sh
Operating Cash Flow Q1 2025 · Mar 31, 2025 −€33.28M
Operating Cash Flow Q1 2025 · Mar 31, 2024 −€34.75M
Cash And Equivalents Q1 2025 · Mar 31, 2025 €103.58M
Cash And Equivalents Q1 2025 · Dec 31, 2024 €144.22M
Cash And Equivalents Q1 2025 · Mar 31, 2024 €241.61M
Cash And Equivalents Q1 2025 · Dec 31, 2023 €251.94M
Stockholders Equity Q1 2025 · Mar 31, 2025 −€6.59M
Stockholders Equity Q1 2025 · Dec 31, 2024 €40.58M
Stockholders Equity Q1 2025 · Mar 31, 2024 €158.87M
Stockholders Equity Q1 2025 · Dec 31, 2023 €196.01M
Current Liabilities Q1 2025 · Mar 31, 2025 €105.74M
Current Liabilities Q1 2025 · Dec 31, 2024 €94M
Current Assets Q1 2025 · Mar 31, 2025 €132.67M
Current Assets Q1 2025 · Dec 31, 2024 €170.67M
Total Assets Q1 2025 · Mar 31, 2025 €166.94M
Total Assets Q1 2025 · Dec 31, 2024 €205.23M
Eps Diluted Q1 2025 · Mar 31, 2025 −€0.83
Eps Diluted Q1 2025 · Mar 31, 2024 −€0.68
Eps Basic Q1 2025 · Mar 31, 2025 −€0.83
Eps Basic Q1 2025 · Mar 31, 2024 −€0.68
Rd Expense Q1 2025 · Mar 31, 2025 €39.3M
Rd Expense Q1 2025 · Mar 31, 2024 €35.74M
Net Income Q1 2025 · Mar 31, 2025 −€52.37M
Net Income Q1 2025 · Mar 31, 2024 −€42.87M
Operating Income Q1 2025 · Mar 31, 2025 −€47.2M
Operating Income Q1 2025 · Mar 31, 2024 −€44.67M